Medscape is available in 5 Language Editions – Choose your Edition here.


Somogyi Phenomenon

  • Author: Michael Cooperman, MD; Chief Editor: George T Griffing, MD  more...
Updated: Dec 22, 2014


In the 1930s, Dr. Michael Somogyi speculated that hypoglycemia during the late evening induced by insulin could cause a counterregulatory hormone response (see the image below) that produces hyperglycemia in the early morning.[1]

Normal hypoglycemic counterregulation. Normal hypoglycemic counterregulation.

This phenomenon is actually less common than the dawn phenomenon, which is an abnormal early morning increase in the blood glucose level because of natural changes in hormone levels.[2, 3, 4] Debate continues in the scientific community as to the actual presence of this reaction to hypoglycemia. Shanik et al, for example, suggested that the hyperglycemia attributed to the Somogyi phenomenon actually is caused by an insulin-induced insulin resistance.[5]

The causes of Somogyi phenomenon include excess or ill-timed insulin, missed meals or snacks, and inadvertent insulin administration.[6, 7, 8] Unrecognized posthypoglycemic hyperglycemia can lead to declining metabolic control and hypoglycemic complications.

Although no data on frequency are available, Somogyi phenomenon is probably rare. It occurs in diabetes mellitus type 1 and is less common in diabetes mellitus type 2. With proper identification and management, the prognosis for Somogyi phenomenon is excellent, and there is no evidence of long-term sequelae.

Instruct patients in proper identification of symptoms of hypoglycemia, insulin dose, timing of meals, and insulin administration. For patient education information, see Insulin Reaction.



The ability to suppress insulin release is an important physiologic response that people with insulin-requiring diabetes cannot carry out, as displayed in the image below.

Mechanisms of insulin secretion. Mechanisms of insulin secretion.

Defense against hypoglycemia involves counterregulatory hormones, which stimulate gluconeogenesis and glycogenolysis and counteract the anabolic effects of insulin.[5] This mechanism is dependent on an intact glucose sensor system in the CNS, pancreas, and afferent nerves.[9] Counterregulatory hormones include the following:

  • Glucagon acts on the liver to stimulate glycogenolysis and gluconeogenesis and is probably the earliest and most important hormone in the Somogyi phenomenon
  • Epinephrine increases the delivery of substrates from the periphery, decreases insulin release, stimulates glucagon release, inhibits glucose utilization by several tissues, and stimulates a warning system with sweating, anxiety, and tachycardia
  • Cortisol may aid in prolonged and severe cases of Somogyi phenomenon by blocking glucose use and stimulating hepatic glucose output
  • Growth hormones are similar to those of cortisol

Studies have cast doubt on the importance of counterregulatory hormones in mediating glycemic rebound. Hypoinsulinemia (waning of the insulin dose), insulin resistance, and hypersensitivity to the effects of the counterhormones also may play a role.

Choudhary and associates have cast further doubt on the frequency of the Somogyi effect by studying nocturnal hypoglycemia with continuous glucose monitoring. Eighty-nine patients with type 1 diabetes were studied. They compared fasting capillary glucose levels following nights with nocturnal hypoglycemia. They found that capillary fasting glucose was more likely to be lower following nocturnal hypoglycemia with only 2 instances of fasting glucose greater than 180 mgm%. They concluded that the Somogyi effect was rare and the finding of a low fasting glucose was a better indicator of nocturnal hypoglycemia.[10]


Patient History

Patients with Somogyi phenomenon present with morning hyperglycemia out of proportion to their usual glucose control. Nocturnal hypoglycemia is missed or asymptomatic, and posthypoglycemic hyperglycemia is not considered or is confused with the dawn phenomenon.

The most common cause of morning hyperglycemia is hypoinsulinemia. Patients have an increased need for insulin in the early morning primarily due to the release of growth hormone, which antagonizes insulin action. Cortisol may play a supporting role.

Patients may experience falling insulin levels due to absorption or dose issues from the previous evening. This occurs as the insulin requirement is rising (dawn phenomenon) and results in a rapid rise of blood sugar at 4-8 AM. This occurrence is common in people with either type 1 or type 2 diabetes mellitus.


Lab Studies

Laboratory studies for identifying Somogyi phenomenon include fasting blood glucose, nocturnal blood glucose, hemoglobin A1C (Hgb A1C), and frequent glucose sampling.

The fasting blood glucose level is expected to be inappropriately elevated due to hormonally induced rebound. A glucose reading in the middle of the night will disclose hypoglycemia as a result of insulin therapy. This will establish the diagnosis.

Obtaining an Hgb A1C level may be helpful if it is within the reference range or low despite an elevated fasting glucose level. It supports the concept of a rebound fasting hyperglycemia in the face of normal glucose control. An elevated Hgb A1C does not rule out Somogyi phenomenon.

Frequent glucose monitoring may be necessary to confirm the diagnosis and look for other periods of hypoglycemia that may lead to rebound hyperglycemia. Frequent hypoglycemia is responsible for hypoglycemic unawareness, which may cause the typical symptoms of hypoglycemia to be missed.


Treatment & Management

Somogyi phenomenon should be suspected in patients presenting with atypical hyperglycemia in the early morning that resists treatment with increased insulin doses.

If nocturnal blood sugar is confirmatory or if suspicion is high, reduce evening or bedtime insulin. Clinical signs, including weight gain, normal daytime blood sugar levels, and relatively low Hgb A1C, suggest overtreatment.

Substitution of regular insulin with an immediate-acting insulin analog, such as Humulin lispro,[11, 12] may be of some help, but this has not been firmly established.

Consider endocrine or diabetes consultation for difficult or unusual cases.


Continue glucose monitoring with special attention to hypoglycemia in patients with Somogyi phenomenon. Monitor weight, Hgb A1C, and fasting blood glucose levels.

Contributor Information and Disclosures

Michael Cooperman, MD Clinical Associate Professor of Endocrinology, Temple University School of Medicine; Chair, Department of Internal Medicine, Division of Endocrinology, Jeanes Hospital

Michael Cooperman, MD is a member of the following medical societies: Alpha Omega Alpha, American College of Physicians, American Association of Clinical Endocrinologists, Endocrine Society

Disclosure: Nothing to disclose.

Chief Editor

George T Griffing, MD Professor Emeritus of Medicine, St Louis University School of Medicine

George T Griffing, MD is a member of the following medical societies: American Association for the Advancement of Science, International Society for Clinical Densitometry, Southern Society for Clinical Investigation, American College of Medical Practice Executives, American Association for Physician Leadership, American College of Physicians, American Diabetes Association, American Federation for Medical Research, American Heart Association, Central Society for Clinical and Translational Research, Endocrine Society

Disclosure: Nothing to disclose.


Gregory William Rutecki, MD Associate Professor, Program Director, Department of Internal Medicine, Feinberg School of Medicine, Northwestern University

Gregory William Rutecki, MD is a member of the following medical societies: Alpha Omega Alpha, American College of Physicians, American Society of Nephrology, National Kidney Foundation, and Society of General Internal Medicine

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

Kent Wehmeier, MD Professor, Department of Internal Medicine, Division of Endocrinology, Diabetes, and Metabolism, St Louis University School of Medicine

Kent Wehmeier, MD is a member of the following medical societies: American Society of Hypertension, Endocrine Society, and International Society for Clinical Densitometry

Disclosure: Nothing to disclose.

  1. Somogyi M. Insulin as a cause of extreme hyperglycemia and instability. Bull St Louis Med Soc. 1938. 32:498-500.

  2. Bolli GB, Gerich JE. The "dawn phenomenon"--a common occurrence in both non-insulin- dependent and insulin-dependent diabetes mellitus. N Engl J Med. 1984 Mar 22. 310(12):746-50. [Medline].

  3. Campbell PJ, Bolli GB, Cryer PE. Pathogenesis of the dawn phenomenon in patients with insulin-dependent diabetes mellitus. Accelerated glucose production and impaired glucose utilization due to nocturnal surges in growth hormone secretion. N Engl J Med. 1985 Jun 6. 312(23):1473-9. [Medline].

  4. Rybicka M, Krysiak R, Okopie B. The dawn phenomenon and the Somogyi effect - two phenomena of morning hyperglycaemia. Endokrynol Pol. 2011. 62(3):276-84.

  5. Shanik MH, Xu Y, Skrha J, et al. Insulin resistance and hyperinsulinemia: is hyperinsulinemia the cart or the horse?. Diabetes Care. 2008 Feb. 31 Suppl 2:S262-8. [Medline]. [Full Text].

  6. Bolli GB, Gottesman IS, Campbell PJ. Glucose counterregulation and waning of insulin in the Somogyi phenomenon (posthypoglycemic hyperglycemia). N Engl J Med. 1984 Nov 8. 311(19):1214-9. [Medline].

  7. Raskin P. The Somogyi phenomenon. Sacred cow or bull?. Arch Intern Med. 1984 Apr. 144(4):781-7. [Medline].

  8. Somogyi M. Exacerbation of diabetes by excess insulin action. Am J Med. 1959 Feb. 26(2):169-91. [Medline].

  9. McCrimmon R. The mechanisms that underlie glucose sensing during hypoglycaemia in diabetes. Diabet Med. 2008 May. 25(5):513-22. [Medline].

  10. Choudhary P, Davies C, Emery CJ, Heller SR. Do high fasting glucose levels suggest nocturnal hypoglycemia? The Somogyi Effect-more fiction than fact. Diabetic Medicine. 08/2013. 30:914-917.

  11. Singh SR, Ahmad F, Lal A, et al. Efficacy and safety of insulin analogues for the management of diabetes mellitus: a meta-analysis. CMAJ. 2009 Feb 17. 180(4):385-97. [Medline]. [Full Text].

  12. Lind M, Fahlen M, Happich M, et al. The effect of insulin lispro on glycemic control in a large patient cohort. Diabetes Technol Ther. 2009 Jan. 11(1):51-6. [Medline].

Normal hypoglycemic counterregulation.
Mechanisms of insulin secretion.
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.